QUESTIONS / 24 ENTRIES
PT-141 Frequently Asked Questions.
Direct, citation-explicit answers to the questions most often asked about bremelanotide — drawn from the FDA label, the RECONNECT Phase 3 program, and the broader peer-reviewed record.
Definitional
What does the PT-141 peptide do?
PT-141 is a synthetic cyclic heptapeptide analogue of alpha-MSH that activates central melanocortin receptors — principally MC3R and MC4R — in the hypothalamus to modulate sexual arousal pathways [1][2]. The mechanism is distinct from peripheral vasodilator ED drugs: PT-141 acts on the medial preoptic area and paraventricular nucleus, not on penile vasculature [1][12].
What is PT-141?
PT-141 (bremelanotide) is a synthetic melanocortin receptor agonist derived from Melanotan II by deletion of the C-terminal amide [1]. The compound was FDA-approved in June 2019 as the prescription product for hypoactive sexual desire disorder in premenopausal women [3][4]. Molecular formula C50H68N14O10, molecular weight 1025.2 Da, CAS 189691-06-3.
What is PT-141 used for?
Approved by the FDA for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women [3][4]. Studied off-label in male erectile dysfunction in the early 2000s with the discontinued intranasal formulation [9]. No male indication has been approved in any jurisdiction.
How does PT-141 work?
Central nervous system melanocortin receptor agonism. PT-141 activates MC4R-expressing neurons in the medial preoptic area and paraventricular nucleus of the hypothalamus, with downstream dopaminergic signaling through the ventral tegmental area [1][11][12]. The pathway is independent of the nitric oxide / cGMP / PDE5 axis that mediates peripheral vasodilator drug action.
Comparative
Is PT-141 better than Viagra?
Different mechanism, not better. PT-141 acts centrally on melanocortin receptors in the hypothalamus; sildenafil acts peripherally as a PDE5 inhibitor in penile vasculature [1][9][12]. Published trials have examined co-administration in male ED non-responders (Diamond 2005, intranasal PT-141 + sildenafil), not substitution [9]. Direct head-to-head efficacy comparisons in approved indications do not exist.
How does PT-141 compare to Viagra?
Central melanocortin agonism versus peripheral vasodilation — orthogonal mechanisms. Diamond 2005 studied intranasal PT-141 at 7.5 or 10 mg co-administered with sildenafil 25 mg in 32 men with ED who were sildenafil non-responders or partial responders, reporting an additive erectile response on RigiScan testing across a six-hour window [9]. The intranasal formulation was later discontinued.
How consistent are PT-141 results in trials?
The RECONNECT Phase 3 trials (n=1,267) showed statistically significant improvements in the FSFI desire domain and reductions in FSDS-DAO Item 13 distress versus placebo, sustained in the open-label extension to ~76 weeks [3][6]. Independent re-analysis (Spielmans 2021) argued the clinical magnitude of benefit was modest and below thresholds some authors consider clinically meaningful; dropout exceeded placebo in the active arm [14]. Both findings sit in the published record.
Pharmacokinetic and dosing
How long does PT-141 last?
Plasma half-life of approximately 1.9-4 hours following subcutaneous administration, with subjective effect window reported by trial subjects extending several hours post-dose [4]. The 2022 JCI fMRI study documented self-reported sexual desire elevation up to 24 hours post a single 1.75 mg SC dose in premenopausal HSDD women [17].
How long does it take for PT-141 to kick in?
The label directs administration at least 45 minutes before anticipated sexual activity, calibrated to a median Tmax of approximately 1.0-1.5 hours after subcutaneous dosing [4][7].
How fast does PT-141 work?
Subcutaneous Tmax around 1.0-1.5 hours. The label directs dosing 45 minutes before anticipated activity [4][7].
How much PT-141 to inject?
The approved dose is 1.75 mg subcutaneous as a single use per occasion via prefilled autoinjector [4][7]. The Phase 2b dose-ranging program tested 0.75, 1.25, and 1.75 mg arms; 1.75 mg was selected for Phase 3 [8]. Historical intranasal male-ED trials used 7.5-10 mg before the SC reformulation was approved [9].
Where to inject PT-141?
The label specifies subcutaneous administration into the abdomen or the thigh via the single-use autoinjector [4][7].
Can you use PT-141 every day?
The label caps use at no more than one dose per 24 hours and no more than eight doses per month [4][7]. Trial protocols did not study daily chronic dosing in the approved indication. Eight-day continuous daily dosing was examined only in pharmacokinetic and safety substudies and was associated with a markedly elevated focal hyperpigmentation rate (~38% versus ~1% at label-cap frequency) [4].
When to take PT-141?
At least 45 minutes before anticipated sexual activity, no more than one dose per 24 hours, no more than eight doses per month [4][7].
Safety
What are the side effects of bremelanotide?
Nausea (~40% of trial participants), flushing (~20%), headache (~11%), injection-site reactions (~5%), transient blood pressure elevation (mean +1.9 mmHg systolic over 24 hours with +2.8 mmHg peak at 4-8 hours), and focal hyperpigmentation (~1% at label-cap dosing) [3][4][5][19]. Nausea was the leading adverse event and the leading reason for discontinuation.
Does PT-141 darken skin?
Yes — focal hyperpigmentation was reported in approximately 1% of Vyleesi trial subjects at label-cap dosing, primarily on the face, gingiva, and breasts; partially reversible after discontinuation, not confirmed in all cases [4][5]. Mechanism is MC1R cross-activity on cutaneous melanocytes. Frequency rose to approximately 38% with eight consecutive days of daily dosing in a safety substudy [4].
Does PT-141 make you tan?
PT-141 has lower MC1R affinity than its parent compound Melanotan II [1], so generalized tanning is uncommon at label-defined dosing frequency. The documented finding in the trial record is focal hyperpigmentation rather than systemic tanning [4][5].
Does PT-141 really work?
RECONNECT Phase 3 trials (n=1,267 premenopausal HSDD subjects) showed statistically significant improvements in the FSFI desire domain and FSDS-DAO Item 13 distress versus placebo [3]. Independent re-analysis (Spielmans 2021) characterized the effect-size magnitude as modest [14]. The 2022 JCI fMRI study documented mechanistic neuroimaging confirmation in the target population [17].
Interaction and storage
Can you take PT-141 with Viagra?
Diamond 2005 reported an additive erectile response with intranasal PT-141 at 7.5 or 10 mg + sildenafil 25 mg in 32 men with ED on RigiScan testing across a six-hour window [9]. The modern Vyleesi label does not include PDE5 inhibitor co-administration guidance, and concomitant blood-pressure effects of both classes argue for caution.
PT-141 and tadalafil
Can you take PT-141 with Cialis? Co-administration with long-acting PDE5 inhibitors has not been systematically studied. The blood-pressure effects of both agents argue for caution in any future trial design [4][19].
PT-141 storage stability
Does PT-141 need to be refrigerated? The Vyleesi autoinjector is stored at room temperature per the label [7]. Lyophilized research-grade vials are typically stored refrigerated or frozen; reconstituted solution in bacteriostatic water is typically refrigerated and used within weeks per peptide-stability literature.
Regulatory
Is PT-141 legal in the US?
Bremelanotide is FDA-approved as the prescription product for premenopausal HSDD (June 2019, NDA 210557) and is available by prescription in the United States [3][4]. Research-grade PT-141 sold outside that channel is marketed for laboratory use only and is not the approved product.
FDA approval status
Is PT-141 FDA approved? Yes — bremelanotide was approved by the FDA on 2019-06-21 under NDA 210557 for acquired, generalized hypoactive sexual desire disorder in premenopausal women [3][4]. Marketing authorization was also granted in the European Union in 2019; commercial availability has varied by member state. Other indications remain investigational.